Kronos Bio (NASDAQ:KRON) Issues Earnings Results

Kronos Bio (NASDAQ:KRON) released its earnings results on Tuesday. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.13), Zacks reports. Kronos Bio had a negative return on equity of 64.55% and a negative net margin of 867.66%.

Kronos Bio Trading Down 0.1 %

Shares of KRON stock traded down $0.00 during trading hours on Tuesday, hitting $0.95. The company’s stock had a trading volume of 117,250 shares, compared to its average volume of 270,226. The business has a fifty day moving average of $0.98 and a 200-day moving average of $0.96. Kronos Bio has a twelve month low of $0.69 and a twelve month high of $1.60. The stock has a market cap of $57.20 million, a price-to-earnings ratio of -0.66 and a beta of 1.79.

Kronos Bio Company Profile

Kronos Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma.